EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

被引：183

作者：

Lam, Thomas B. L. ^{[1
,2
]}

MacLennan, Steven ^{[1
]}

Willemse, Peter-Paul M. ^{[3
]}

Mason, Malcolm D. ^{[4
]}

Plass, Karin ^{[5
]}

Shepherd, Robert ^{[5
]}

Baanders, Ruud

Bangma, Chris H. ^{[6
]}

Bjartell, Anders ^{[7
]}

Bossi, Alberto ^{[8
]}

Briers, Erik

Briganti, Alberto ^{[9
,10
]}

Buddingh, Karel T. ^{[11
]}

Cattom, James W. F. ^{[12
,13
]}

Colecchia, Maurizio ^{[14
]}

Cox, Brett W. ^{[15
]}

Cumberbatch, Marcus G. ^{[12
]}

Davies, Jeff

Davis, Niall F. ^{[16
,17
]}

De Santis, Maria ^{[18
]}

Dell'Oglio, Paolo ^{[19
,20
]}

Deschamps, Andre ^{[21
]}

Donaldson, James F. ^{[1
,2
]}

Egawa, Shin ^{[22
]}

Fankhauser, Christian D. ^{[23
]}

Fanti, Stefano ^{[24
]}

Fossati, Nicola ^{[25
,26
]}

Gandaglia, Giorgio ^{[19
]}

Gillessen, Silke ^{[25
,26
,27
]}

Grivas, Nikolaos ^{[28
]}

Gross, Tobias ^{[29
]}

Grummet, Jeremy P. ^{[30
]}

Henry, Ann M. ^{[31
]}

Ingels, Alexandre ^{[32
]}

Irani, Jacques ^{[33
]}

Lardas, Michael ^{[34
]}

Liew, Matthew ^{[35
]}

Lin, Daniel W. ^{[36
,37
]}

Moris, Lisa ^{[38
,39
]}

Omar, Muhammad Imran ^{[1
]}

Pang, Karl H. ^{[12
]}

Paterson, Catherine C. ^{[1
,40
,41
,69
]}

Renard-Penna, Raphaele ^{[42
]}

Ribal, Maria J. ^{[43
]}

Roobol, Monique J. ^{[6
]}

Roupret, Morgan ^{[44
]}

Rouviere, Olivier ^{[45
,46
]}

Pardo, Gemma Sancho ^{[47
]}

Richenberg, Jonathan ^{[48
,49
]}

Schoots, Ivo G. ^{[50
]}

机构：

[1] Univ Aberdeen, Acad Urol Unit, 2nd Floor,Hlth Sci Bldg, Aberdeen AB25 2ZD, Scotland

[2] Aberdeen Royal Infirm, Dept Urol, Aberdeen, Scotland

[3] Univ Utrecht, Dept Urol, Utrecht, Netherlands

[4] Cardiff Univ, Velindre Canc Ctr, Sch Med, Div Canc & Genet, Cardiff, S Glam, Wales

[5] EAU Guidelines Off, Arnhem, Netherlands

[6] Erasmus MC, Dept Urol, Rotterdam, Netherlands

[7] Lund Univ, Skane Univ Hosp Malmo, Dept Urol, Lund, Sweden

[8] Gustave Roussy Inst, Dept Radiat Oncol, Villejuif, France

[9] Sci Inst, Dept Urol, Milan, Italy

[10] Univ Vita Salute, San Raffaele Hosp, Milan, Italy

[11] HagaZiekenhuis, The Hague, Netherlands

[12] Univ Sheffield, Acad Urol Unit, Sheffield, S Yorkshire, England

[13] Sheffield Teaching Hosp NHS Fdn Trust, Royal Hallamshire Hosp, Dept Urol, Sheffield, S Yorkshire, England

[14] Fdn Irccs Ist Nazl Tumori Milano, Dept Pathol, Uropathol Unit, Milan, Italy

[15] Zucker Sch Med, Dept Radiat Med, New York, NY USA

[16] Beaumont & Connolly Hosp, Dept Urol, Dublin, Ireland

[17] Royal Coll Surgeons Ireland, Dublin, Ireland

[18] Charite, Dept Urol, Berlin, Germany

[19] IRCCS Osped San Raffaele, Urol Res Inst, Div Oncol, Unit Urol, Milan, Italy

[20] ORSI Acad, Melle, Belgium

[21] Europa Uomo, Antwerp, Belgium

[22] Jikei Univ, Sch Med, UAA, Asian Sch Urol, Tokyo, Japan

[23] Univ Zurich, Dept Urol, Zurich, Switzerland

[24] Univ Bologna, Policlin S Orsola, Dept Nucl Med, Bologna, Italy

[25] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[26] Christie, Manchester, Lancs, England

[27] Univ Bern, Cantonal Hosp St Gallen, Dept Med Oncol & Haematol, Bern, Switzerland

[28] Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands

[29] Univ Bern, Dept Urol, Bern, Switzerland

[30] Monash Univ, Dept Surg, Cent Clin Sch, Melbourne, Vic, Australia

[31] St James Univ Hosp, Leeds Canc Ctr, Leeds, W Yorkshire, England

[32] Henri Mondor Hosp, Dept Urol, Creteil, France

[33] Saclay Univ, Paris Sud, Univ Hosp Bicetre, Le Kremlin Bicetre, France

[34] Metropolitan Gen, Dept Reconstruct Urol & Surg Androl, Athens, Greece

[35] Wigan & Leigh NHS Fdn Trust, Dept Urol, Wigan, England

[36] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci, Canc Prevent Program, 1124 Columbia St, Seattle, WA 98104 USA

[37] Univ Washington, Dept Urol, Seattle, WA 98195 USA

[38] Univ Hosp Leuven, Dept Urol, Leuven, Belgium

[39] Katholieke Univ Leuven, Lab Mol Endocrinol, Leuven, Belgium

[40] Univ Canberra, Leuven Sch Nursing Midwifery &, Canberra, ACT, Australia

[41] Robert Gordon Univ, Sch Nursing & Midwifery, Aberdeen, Scotland

[42] Sorbonne Univ, Hop Pitie Salpetriere, Hop Tenon, AP HP,Acad Dept Radiol,GRC,ONCOTYPE URO, Paris, France

[43] Univ Barcelona, Hosp Clin, Urooncol Unit, Barcelona, Spain

[44] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Urol Dept,GRC Ndeg 5,ONCOTYPE URO, Paris, France

[45] Hop Edouard Herriot, Dept Urinary & Vasc Imaging, Hosp Civils Lyon, Lyon, France

[46] Univ Lyon 1, Univ Lyon, Fac Med Lyon Est, Lyon, France

[47] Hosp Santa Creu & Sant Pau, Dept Radiat Oncol, Barcelona, Spain

[48] Royal Sussex Cty Hosp Brighton, Brighton, E Sussex, England

[49] Brighton & Sussex Med Sch, Brighton, E Sussex, England

[50] Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands

来源：

EUROPEAN UROLOGY | 2019年 / 76卷 / 06期

关键词：

Deferred treatment with curative intent; Active surveillance and monitoring; Localised prostate cancer; Eligibility; Follow-up; Reclassification; Outcome measures; Consensus statements; Delphi survey; Consensus group meeting; Clinical practice guidelines; CORE OUTCOME SET; ACTIVE SURVEILLANCE; MANAGEMENT;

D O I：

10.1016/j.eururo.2019.09.020

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers. (C) 2019 Published by Elsevier B.V. on behalf of European Association of Urology.

引用

页码：790 / 813

页数：24

共 23 条

[1] 20-year outcomes following conservative management of clinically localized prostate cancer [J].

Albertsen, PC ;

Hanley, JA ;

Fine, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101

[2]

[Anonymous], 2017, TRIALS, DOI DOI 10.1186/S13063-017-1788-8

[3] Development of a Core Outcome Set for Clinical Effectiveness Trials in Esophageal Cancer Resection Surgery [J].

Avery, Kerry N. L. ;

Chalmers, Katy A. ;

Brookes, Sara T. ;

Blencowe, Natalie S. ;

Coulman, Karen ;

Whale, Katie ;

Metcalfe, Chris ;

Blazeby, Jane M. .

ANNALS OF SURGERY, 2018, 267 (04) :700-710

[4] A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment [J].

Bokhorst, Leonard P. ;

Valdagni, Riccardo ;

Rannikko, Antti ;

Kakehi, Yoshiyuki ;

Pickles, Tom ;

Bangma, Chris H. ;

Roobol, Monique J. .

EUROPEAN UROLOGY, 2016, 70 (06) :954-960

[5] Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic Review [J].

Boulkedid, Rym ;

Abdoul, Hendy ;

Loustau, Marine ;

Sibony, Olivier ;

Alberti, Corinne .

PLOS ONE, 2011, 6 (06)

[6] The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date [J].

Bruinsma, Sophie M. ;

Zhang, Liying ;

Roobol, Monique J. ;

Bangma, Chris H. ;

Steyerberg, Ewout W. ;

Nieboer, Daan ;

Van Hemelrijck, Mieke .

BJU INTERNATIONAL, 2018, 121 (05) :737-744

[7] Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure [J].

Bruinsma, Sophie M. ;

Roobol, Monique J. ;

Carroll, Peter R. ;

Klotz, Laurence ;

Pickles, Tom ;

Moore, Caroline M. ;

Gnanapragasam, Vincent J. ;

Villers, Arnauld ;

Rannikko, Antti ;

Valdagni, Riccardo ;

Frydenberg, Mark ;

Kakehi, Yoshiyuki ;

Filson, Christopher P. ;

Bangma, Chris H. .

NATURE REVIEWS UROLOGY, 2017, 14 (05) :312-+

[8] Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study [J].

Bul, Meelan ;

Zhu, Xiaoye ;

Valdagni, Riccardo ;

Pickles, Tom ;

Kakehi, Yoshiyuki ;

Rannikko, Antti ;

Bjartell, Anders ;

van der Schoot, Deric K. ;

Cornel, Erik B. ;

Conti, Giario N. ;

Boeve, Egbert R. ;

Staerman, Frederic ;

Vis-Maters, Jenneke J. ;

Vergunst, Henk ;

Jaspars, Joris J. ;

Stroelin, Petra ;

van Muilekom, Erik ;

Schroder, Fritz H. ;

Bangma, Chris H. ;

Roobol, Monique J. .

EUROPEAN UROLOGY, 2013, 63 (04) :597-603

[9]

Glasziou TG., OXFORD LEVELS EVIDEN, V2

[10] 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer [J].

Hamdy, F. C. ;

Donovan, J. L. ;

Lane, J. A. ;

Mason, M. ;

Metcalfe, C. ;

Holding, P. ;

Davis, M. ;

Peters, T. J. ;

Turner, E. L. ;

Martin, R. M. ;

Oxley, J. ;

Robinson, M. ;

Staffurth, J. ;

Walsh, E. ;

Bollina, P. ;

Catto, J. ;

Doble, A. ;

Doherty, A. ;

Gillatt, D. ;

Kockelbergh, R. ;

Kynaston, H. ;

Paul, A. ;

Powell, P. ;

Prescott, S. ;

Rosario, D. J. ;

Rowe, E. ;

Neal, D. E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (15) :1415-1424

← 1 2 3 →